The Tiered Panel
A good testing program is not a flat list of 60 markers — it is a hierarchy, and the hierarchy does most of the work. Some tests earn an annual slot because the disease they hunt is silent for decades. Some deserve exactly one draw in a lifetime. And some belong only when symptoms or risk factors point at them, because running them on everyone manufactures more false alarms than findings. This page builds the tiers.
What the evidence supports
- A short annual core — blood pressure, lipids with ApoB, glucose with HbA1c, and waist — catches the major silent killers years early, on guideline-based screening recommendations.
- A handful of once-only tests (Lp(a), hepatitis C) carry strong guideline support and never need repeating.
- Symptom-driven testing avoids most false-positive cascades, because low pretest probability makes most positives false.
What remains uncertain
- No trial randomizes "tiered panel" against "flat panel" — the hierarchy is inference built on screening principles, not a single experiment.
- The exact annual frequency for low-risk adults is consensus more than evidence.
- Where borderline markers (fasting insulin, vitamin D) belong in the tiers is genuinely debated.
Evidence last reviewed: August 15, 2026. Conclusions may change as new research is published.
the hierarchy does the work
Why a Hierarchy at All
Every test you run costs two things: money, and the chance of a false positive that sends you down a cascade of follow-up tests, worry, and sometimes procedures you never needed. Screening only makes sense when the math works out. The classic framework comes from a 1968 World Health Organization report by Wilson and Jungner that still frames modern screening policy — a condition deserves screening when it has a recognizable early phase, an accepted treatment, and evidence that treating it early beats treating it late.
- 🔕 Long silent phase. The longer a disease hides, the more a scheduled test earns its slot — symptoms would have shown up already for anything fast.
- 🧭 Decision-changing result. A test only earns its place if the number changes what you do. If every possible answer leads to "observe," it is data collection, not medicine — the rule the parent topic sets out.
- 🧮 Favorable false-positive math. When few people have the condition, most positives are false. A test that is 95% specific, used on a condition only 1 in 100 screened people actually has, returns a positive that is wrong roughly five times in six. Testing only people with symptoms or risk fixes the arithmetic.
Tier 1: The Annual Core
These four earn their yearly slot on all three criteria: the diseases they track are silent for years, the tests are cheap, and the results change decisions immediately. Each one has its own page in this pillar, so here is one line per test and a link to the deep dive.
- 🫀 Blood pressure. The most consequential vital sign we have — treatable at every stage, measurable free at home. The blood pressure topic owns the categories and the measurement ritual.
- 🧪 ApoB (plus a standard lipid panel). Particle number drives atherosclerosis from your twenties onward, and it responds to diet, drugs, and time. The lipid-panel topic explains why ApoB outranks LDL as the number to watch.
- 🩸 Fasting glucose and HbA1c. The pair that catches prediabetes in its silent, reversible decade. Glucose 101 covers what the two measurements do and do not see.
- 📏 Waist and waist-to-height. The free, monthly, home-owned proxy for visceral fat — the depot that drives metabolic risk. The visceral-fat topic has the tape-measure method.
- 🔑 Fasting insulin, when borderline. Not a universal annual line — it earns a yearly slot when glucose or waist are creeping, because insulin rises years before glucose does. The insulin-resistance topic has the numbers.
Tier 2: Once, or Rarely
Some tests are one-time facts about you, not ongoing measurements — and some are worth doing once only at a specific moment in life. The honest catch: this tier includes one popular test (TSH) that the evidence never quite blessed, which is itself a lesson in how the hierarchy earns its keep.
- 🧬 Lp(a) — once in adulthood. A genetically set, stable lipoprotein that independently raises cardiovascular risk. One draw tells you a fact about your genes; it never needs repeating.
- 🦠 Hepatitis C — once, per universal screening. The CDC recommends every adult be screened at least once, regardless of risk factors (MMWR, 2020). Untreated hepatitis C quietly damages the liver for decades; treatment is now short and effective — a textbook Wilson–Jungner case.
- 💓 Coronary calcium scan — once, at intermediate risk. The one imaging test with genuine decision value, most useful in your 40s–50s when borderline lipids leave the statin question open. The cadence and cost page covers what it costs and when it pays.
- 🧭 TSH — a judgment call, not a mandate. Many clinicians check thyroid function once in midlife. The honest version: the US Preventive Services Task Force finds insufficient evidence to screen symptom-free adults routinely. A single TSH around age 40–50 is defensible as a baseline; a yearly TSH is not evidence-based.
- ☀️ Vitamin D — not a routine screen. Guideline bodies explicitly discourage population-wide vitamin D testing (the Endocrine Society's Choosing Wisely list says the same). Test only with risk — low sun exposure, osteoporosis, malabsorption — or a specific question.
Tier 3: Only With Symptoms or Risk
Everything in this tier is a real test with a real niche — and a poor screening tool. The problem is the false-positive math from the top of this page: without a reason to test, the condition is rare, so most positives are noise. With a reason — a symptom, an exposure, a medication — the pretest probability rises and the test becomes worth its slot.
- 🧲 Ferritin. The iron-storage marker belongs on the panel with fatigue, heavy menstrual bleeding, a vegetarian or vegan diet with endurance training, or suspected iron overload — not as a yearly line.
- 💊 B12. Worth checking with neuropathy, memory complaints, long-term metformin use, age over 60, or a plant-based diet without supplementation.
- 👨 Testosterone. With specific symptoms — low libido, fatigue, loss of muscle — the right protocol is two morning draws, not one, and interpretation belongs to a clinician. The men's-health pillar page covers the decline story and the symptom threshold.
- 🧘 Cortisol. Cortisol pulses hourly, so a single snapshot proves little. Testing makes sense only when a clinician suspects a specific adrenal disorder — not for "adrenal fatigue," which endocrinology societies do not recognize as a diagnosis. The stress pillar explains what cortisol is actually doing.
- 🧭 Thyroid follow-ups. Once a TSH is abnormal, repeat testing and a fuller panel become a clinician question — the follow-up tier, where the calendar yields to the conversation.
The Hidden Tier: What You Don't Pay For
The most valuable tier of the panel never shows up on a lab invoice. These measurements are free, take minutes, and predict more than most of what the wellness market sells.
- 💪 Grip strength. A handgrip dynamometer costs less than a dinner and grip predicts outcomes better than many blood tests. The exercise pillar's hidden-vital-signs topic has the norms.
- 🦩 Single-leg balance and sit-to-stand. Fall risk and lower-body strength, measured in your kitchen in under a minute.
- 📏 The tape measure. Waist monthly, waist-to-height ratio — the cheapest metabolic vital sign there is.
- 😴 Sleep quality. One bad night moves glucose, blood pressure, and stress hormones the next morning — sleep is a pre-analytical variable you control, and the sleep pillar owns the repair shift.
The Tiered Panel at a Glance
| Tier | Tests | Frequency | The decision it changes |
|---|---|---|---|
| 🟢 Tier 1 — annual core | Blood pressure, lipids + ApoB, glucose + HbA1c, waist (add fasting insulin if borderline) | Every 1–2 years; yearly with any risk factor | Start or adjust treatment years before symptoms would have appeared |
| 🔵 Tier 2 — once or rarely | Lp(a), hepatitis C antibody, CAC scan (if intermediate risk), TSH (judgment call) | Once in adulthood; CAC once in 40s–50s | Lifetime risk context and a single well-timed decision point |
| 🟡 Tier 3 — symptoms or risk only | Ferritin, B12, testosterone, cortisol, vitamin D | When symptoms, exposure, or medication point at them | Confirm or exclude a specific suspicion — with the false-positive math on your side |
| ⚪ The free tier | Grip, balance, sit-to-stand, gait, waist, sleep quality | Monthly to quarterly at home | Functional decline and metabolic drift, caught before the lab does |
⚠️ Symptoms outrank the calendar
The tiers govern testing in people who feel fine. Chest pain, unexplained weight loss, blood in the stool, or a new and persistent headache is not a scheduling question — it is a see-a-clinician-now question, regardless of when your next annual draw falls. And anyone with a family history of early heart disease, diabetes, or cancer may belong in a higher tier than their age suggests. Screening schedules should be individualized with a qualified healthcare professional.
Questions, Answered Briefly
- ❓ Does a healthy 30-year-old need an annual panel? Blood pressure and waist, yes — they cost nothing and start anytime. Full blood work is reasonable every 1–2 years from the 30s, with the once-only tests (Lp(a), hepatitis C) worth more at that age than an extra annual draw.
- ❓ Should vitamin D ride along on my yearly draw? Only with a reason — low sun exposure, osteoporosis, malabsorption. Routine screening is explicitly discouraged by guideline bodies; most people end up supplementing by habit rather than by lab value anyway.
- ❓ What bumps a test up a tier? Family history of early disease, a medication that needs monitoring, pregnancy, a prior abnormal value, or a new symptom. Tiers are defaults, not verdicts.
- ❓ Is fasting insulin worth adding if my glucose is normal? It is the early-warning line that glucose alone cannot see, and it earns its slot when waist or glucose are borderline — the insulin-resistance topic walks through the numbers.
The Bottom Line
- Think tiers, not lists — the annual core, the once-in-a-lifetime draws, the symptom-triggered tier, and the free tier each earn their place differently.
- Annual belongs to the silent killers — pressure, ApoB/lipids, glucose/HbA1c, and waist, with insulin joining when things creep.
- Once-in-a-lifetime tests are underpriced decisions — Lp(a) and hepatitis C take one draw each and shape decades of context.
- Symptoms and risk outrank the calendar — the tiers are for people who feel fine; anything new or persistent is a clinician conversation.
Related Topics
- Wilson & Jungner, "Principles and Practice of Screening for Disease," World Health Organization (1968)
- US Preventive Services Task Force, current screening recommendations for hypertension, dyslipidemia, diabetes, and hepatitis C
- American Diabetes Association, "Standards of Care in Diabetes," Diabetes Care (2024)
- Mach et al., "2019 ESC/EAS guidelines for the management of dyslipidaemias," European Heart Journal (2020)
- Schillie et al., "CDC recommendations for hepatitis C screening among adults — United States, 2020," MMWR Recommendations and Reports (2020)
- Strong et al., "Prevalence and extent of atherosclerosis in adolescents and young adults," JAMA (1999)
- Knowler et al., "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin," New England Journal of Medicine (2002)
- Hecht et al., "2016 SCCT/STR guidelines for coronary artery calcium scoring," Journal of Cardiovascular Computed Tomography (2017)